This application supports the participation of the University of the Chicago Comprehensive Cancer Center (UCCCC) as a Lead Academic Participating Site in the National Clinical Trials Network (NCTN). The NCTN develops and performs state-of-the-art early and late stage clinical trials for the treatment of adults with cancer. UCCCC is a long-standing member of the Alliance for Clinical Trials in Oncology, the Radiation Therapy Oncology Group, and the Gynecologic Oncology Group. The UCCCC will provide multi-disciplinary scientific and administrative leadership in the design of innovative and potentially practice-changing clinical trials within the NCTN. UCCCC faculty members will contribute to the NCTN as operational leaders, committee chairs, committee vice-chairs, committee leaders, and study chairs, and as members of NCI Advisory and Scientific Committees. Preliminary studies performed by UCCCC investigators at the University of Chicago through the U0l Phase 1 Cooperative Agreement and the N0I Phase 1 Clinical Trials Contract will be brought to the NCTN for large scale testing. Laboratories at the University of Chicago will perform correlative studies that will support NCTN trials. University of Chicago senior faculty will mentor young investigators to become future leaders in the NCTN. The UCCCC has the infrastructure for the initiation and conduct of a wide spectrum of clinical trials, supported through the Cancer Clinical Trials Office (CCTO), a formal Core Facility of the Cancer Center Support Grant, which manages the regulatory activities for all adult cancer-related clinical trials. The NCTN Lead Academic Participating Site Program activities at UCCCC will be coordinated by a Steering Committee of 4 Principal Investigators who represent medical, surgical, radiation, and gynecologic oncology, and 2 senior administrative leaders in the UCCCC. The Steering Committee will oversee the NCTN Coordinating Center in the Cancer Clinical Trials Office, which will provide centralized regulatory oversight and data quality contro support for the implementation, quality execution of, and efficient accrual to, NCTN trials across the Network. UCCCC will collaborate with the Network Group Operations Centers and the associated Network Group Statistics and Data Management Centers to achieve the research goals of the NCTN program. The UCCCC will thus provide a mechanism for robust accrual to trials across the NCTN, with participation across all tumor types, including trials for rare cancer and in a diverse patient population, at UCCCC and 9 /Affiliate institutions.

Public Health Relevance

NCTN trials set the standards for cancer treatment in the United States and across the world. The significant recent advances in the basic sciences cannot benefit patients unless new treatments are proven safe and beneficial in the clinical setting, UCCCC will contribute to the goals of the NCTN by providing the scientific leadership to develop trials that have a significant impact on treatment and the infrastructure to effectively accrue to clinical trials across the NCTN.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180836-04
Application #
9237235
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-04-28
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
$634,404
Indirect Cost
$233,009
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
Innocenti, Federico; Jiang, Chen; Sibley, Alexander B et al. (2018) Genetic variation determines VEGF-A plasma levels in cancer patients. Sci Rep 8:16332
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328
McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31
Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Guercio, Brendan J; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One 13:e0199244

Showing the most recent 10 out of 30 publications